Optimized (pre)analytical conditions and workflow for droplet digital PCR analysis of cell-Free DNA from patients with suspected lung carcinoma

Remco de Kock (Corresponding author), Birgit Deiman, Raisa Kraaijvanger, Volkher Scharnhorst

Research output: Contribution to journalArticleAcademicpeer-review

1 Downloads (Pure)

Abstract

For patients with suspected lung carcinoma, the analysis of circulating tumor DNA, obtained by liquid biopsy, has the potential to support cancer diagnosis and guide targeted therapy. To ensure sensitive and reproducible detection of circulating tumor DNA in routine clinical practice, a standardized (pre) analytical workflow is required. Plasma was obtained from patients and healthy volunteers. Using the QIAmp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany), six different procedures for the isolation of cell-free DNA (cfDNA) were compared. cfDNA was analyzed by droplet digital PCR (ddPCR) for KRAS G12/13 mutations and for EGFR Ex19Del, L858R, and L861Q mutations using an in-house EGFR multiplex assay. A new isolation procedure that yields extracts with significantly higher cfDNA concentrations than described previously was selected (P < 0.001). EGFR and KRAS assay sensitivity of at least 0.2% fractional abundance was guaranteed for approximately 76% of patient samples in one run. A flowchart that includes validity criteria for a standardized analytical workflow of ddPCR analysis was designed. An improved protocol for cfDNA isolation enables a higher cfDNA input for ddPCR. The use of sensitive KRAS and EGFR multiplex assays and accompanying validity criteria allows for controlled and efficient testing of patient samples at lower costs. Using the suggested workflow, a guaranteed, reliable, and sensitive analysis of cfDNA can be performed using ddPCR in routine clinical practice.

Original languageEnglish
Pages (from-to)895-902
Number of pages8
JournalThe Journal of Molecular Diagnostics
Volume21
Issue number5
DOIs
Publication statusPublished - 1 Sep 2019

Fingerprint

Workflow
Carcinoma
Polymerase Chain Reaction
Lung
DNA
Software Design
Neoplasms
Mutation
Cell Separation
Nucleic Acids
Germany
Healthy Volunteers
Biopsy
Costs and Cost Analysis

Cite this

@article{bc98180ec4054069938d357c14505f2b,
title = "Optimized (pre)analytical conditions and workflow for droplet digital PCR analysis of cell-Free DNA from patients with suspected lung carcinoma",
abstract = "For patients with suspected lung carcinoma, the analysis of circulating tumor DNA, obtained by liquid biopsy, has the potential to support cancer diagnosis and guide targeted therapy. To ensure sensitive and reproducible detection of circulating tumor DNA in routine clinical practice, a standardized (pre) analytical workflow is required. Plasma was obtained from patients and healthy volunteers. Using the QIAmp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany), six different procedures for the isolation of cell-free DNA (cfDNA) were compared. cfDNA was analyzed by droplet digital PCR (ddPCR) for KRAS G12/13 mutations and for EGFR Ex19Del, L858R, and L861Q mutations using an in-house EGFR multiplex assay. A new isolation procedure that yields extracts with significantly higher cfDNA concentrations than described previously was selected (P < 0.001). EGFR and KRAS assay sensitivity of at least 0.2{\%} fractional abundance was guaranteed for approximately 76{\%} of patient samples in one run. A flowchart that includes validity criteria for a standardized analytical workflow of ddPCR analysis was designed. An improved protocol for cfDNA isolation enables a higher cfDNA input for ddPCR. The use of sensitive KRAS and EGFR multiplex assays and accompanying validity criteria allows for controlled and efficient testing of patient samples at lower costs. Using the suggested workflow, a guaranteed, reliable, and sensitive analysis of cfDNA can be performed using ddPCR in routine clinical practice.",
author = "{de Kock}, Remco and Birgit Deiman and Raisa Kraaijvanger and Volkher Scharnhorst",
note = "Copyright {\circledC} 2019 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.",
year = "2019",
month = "9",
day = "1",
doi = "10.1016/j.jmoldx.2019.05.003",
language = "English",
volume = "21",
pages = "895--902",
journal = "The Journal of Molecular Diagnostics",
issn = "1525-1578",
publisher = "Elsevier",
number = "5",

}

Optimized (pre)analytical conditions and workflow for droplet digital PCR analysis of cell-Free DNA from patients with suspected lung carcinoma. / de Kock, Remco (Corresponding author); Deiman, Birgit; Kraaijvanger, Raisa; Scharnhorst, Volkher.

In: The Journal of Molecular Diagnostics, Vol. 21, No. 5, 01.09.2019, p. 895-902.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Optimized (pre)analytical conditions and workflow for droplet digital PCR analysis of cell-Free DNA from patients with suspected lung carcinoma

AU - de Kock, Remco

AU - Deiman, Birgit

AU - Kraaijvanger, Raisa

AU - Scharnhorst, Volkher

N1 - Copyright © 2019 American Society for Investigative Pathology and the Association for Molecular Pathology. Published by Elsevier Inc. All rights reserved.

PY - 2019/9/1

Y1 - 2019/9/1

N2 - For patients with suspected lung carcinoma, the analysis of circulating tumor DNA, obtained by liquid biopsy, has the potential to support cancer diagnosis and guide targeted therapy. To ensure sensitive and reproducible detection of circulating tumor DNA in routine clinical practice, a standardized (pre) analytical workflow is required. Plasma was obtained from patients and healthy volunteers. Using the QIAmp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany), six different procedures for the isolation of cell-free DNA (cfDNA) were compared. cfDNA was analyzed by droplet digital PCR (ddPCR) for KRAS G12/13 mutations and for EGFR Ex19Del, L858R, and L861Q mutations using an in-house EGFR multiplex assay. A new isolation procedure that yields extracts with significantly higher cfDNA concentrations than described previously was selected (P < 0.001). EGFR and KRAS assay sensitivity of at least 0.2% fractional abundance was guaranteed for approximately 76% of patient samples in one run. A flowchart that includes validity criteria for a standardized analytical workflow of ddPCR analysis was designed. An improved protocol for cfDNA isolation enables a higher cfDNA input for ddPCR. The use of sensitive KRAS and EGFR multiplex assays and accompanying validity criteria allows for controlled and efficient testing of patient samples at lower costs. Using the suggested workflow, a guaranteed, reliable, and sensitive analysis of cfDNA can be performed using ddPCR in routine clinical practice.

AB - For patients with suspected lung carcinoma, the analysis of circulating tumor DNA, obtained by liquid biopsy, has the potential to support cancer diagnosis and guide targeted therapy. To ensure sensitive and reproducible detection of circulating tumor DNA in routine clinical practice, a standardized (pre) analytical workflow is required. Plasma was obtained from patients and healthy volunteers. Using the QIAmp Circulating Nucleic Acid Kit (Qiagen, Hilden, Germany), six different procedures for the isolation of cell-free DNA (cfDNA) were compared. cfDNA was analyzed by droplet digital PCR (ddPCR) for KRAS G12/13 mutations and for EGFR Ex19Del, L858R, and L861Q mutations using an in-house EGFR multiplex assay. A new isolation procedure that yields extracts with significantly higher cfDNA concentrations than described previously was selected (P < 0.001). EGFR and KRAS assay sensitivity of at least 0.2% fractional abundance was guaranteed for approximately 76% of patient samples in one run. A flowchart that includes validity criteria for a standardized analytical workflow of ddPCR analysis was designed. An improved protocol for cfDNA isolation enables a higher cfDNA input for ddPCR. The use of sensitive KRAS and EGFR multiplex assays and accompanying validity criteria allows for controlled and efficient testing of patient samples at lower costs. Using the suggested workflow, a guaranteed, reliable, and sensitive analysis of cfDNA can be performed using ddPCR in routine clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=85070834558&partnerID=8YFLogxK

U2 - 10.1016/j.jmoldx.2019.05.003

DO - 10.1016/j.jmoldx.2019.05.003

M3 - Article

C2 - 31229652

VL - 21

SP - 895

EP - 902

JO - The Journal of Molecular Diagnostics

JF - The Journal of Molecular Diagnostics

SN - 1525-1578

IS - 5

ER -